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Abstract: A multiple sclerosis (MS) diagnosis often relies upon clinical presentation and qualitative
analysis of standard, magnetic resonance brain images. However, the accuracy of MS diagnoses
can be improved by utilizing advanced brain imaging methods. We assessed the accuracy of a new
neuroimaging marker, visual-evoked cerebral metabolic rate of oxygen (veCMRO2 ), in classifying MS
patients and closely age- and sex-matched healthy control (HC) participants. MS patients and HCs
underwent calibrated functional magnetic resonance imaging (cfMRI) during a visual stimulation task,
diffusion tensor imaging, T1 - and T2 -weighted imaging, neuropsychological testing, and completed
self-report questionnaires. Using resampling techniques to avoid bias and increase the generalizability
of the results, we assessed the accuracy of veCMRO2 in classifying MS patients and HCs. veCMRO2
classification accuracy was also examined in the context of other evoked visuofunctional measures,
white matter microstructural integrity, lesion-based measures from T2 -weighted imaging, atrophy
measures from T1 -weighted imaging, neuropsychological tests, and self-report assays of clinical
symptomology. veCMRO2 was significant and within the top 16% of measures (43 total) in classifying
MS status using both within-sample (82% accuracy) and out-of-sample (77% accuracy) observations.
High accuracy of veCMRO2 in classifying MS demonstrated an encouraging first step toward
establishing veCMRO2 as a neurodiagnostic marker of MS.
Keywords: calibrated functional magnetic resonance imaging; multiple sclerosis; diagnosis;
visual system; metabolism
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1. Introduction
Current procedures for diagnosing multiple sclerosis (MS) rely primarily upon clinical
presentation and qualitative analysis of standard, medical-grade (e.g., lower resolution) magnetic
resonance structural, brain images, e.g., [1]. It has been demonstrated that the diagnostic accuracy of
MS can be improved when providers implement advanced neuroimaging techniques and analyses that
are not presently common in clinical practice, e.g., [2], see also [3]. Further, research using advanced
neuroimaging techniques has demonstrated that these techniques can be more sensitive than their
traditional counterparts in detecting subtle changes associated with very early manifestations of MS,
e.g., [4,5]. Here, we investigated the accuracy of an advanced neuroimaging technique never before
used in MS, calibrated functional magnetic resonance imaging (cfMRI), to classify MS patients and
closely age- and sex-matched healthy controls (HCs). Specifically, we focused our analyses upon the
ability of a new neuroimaging marker, visual-evoked cerebral metabolic rate of oxygen (veCMRO2 ),
to accurately discriminate between MS patients and HCs.
cfMRI is a relatively new neuroimaging technique that capitalizes upon established relationships
between blood-oxygen-level dependent (BOLD) signal and cerebral blood flow (CBF) in order to
estimate steady-state, oxygen metabolism [6,7] see [8]. The technique gets its name from the use
of a BOLD-calibration parameter, often acquired during a gas-inhalation challenge. The CMRO2
metric permitted by cfMRI offers several advantages over the more commonly used BOLD signal.
First, CMRO2 offers physiological specificity. CMRO2 represents a true physiological process, oxygen
metabolism, whereas BOLD reflects a confluence of processes and as such, is physiologically
non-specific. Second, calibration-derived CMRO2 is strongly tied to electrical and chemical neural
activity, e.g., [9–15], whereas an appreciable component of BOLD signal is unexplained by neural
activity, e.g., [16–20], see [21], but see [9]. Finally, CMRO2 measures are not dependent upon the
hemodynamic assumptions of BOLD, making them optimal measures of brain function in populations
with atypical hemodynamics, like MS, e.g., [22,23], see [24].
Evaluating CMRO2 as a diagnostic marker of MS is particularly relevant for these patients
because MS is associated with changes to neurometabolism. Neuroimaging research has produced
considerable evidence of altered neurometabolism in MS, e.g., [25–29]. In one study, Ge and
colleagues [30] demonstrated decreases in brain-wide resting CMRO2 for MS patients relative to HCs.
Some neuroimaging studies have shown that neurometabolic alterations were related to white matter
macrostructural (i.e., lesions, e.g., [30]) or microstructural damage in MS, e.g., [27,28]. For example,
magnetic resonance spectroscopy in centrum semiovale white matter has shown that N-acetylaspertate
(NAA) and NAA: creatine ratios were strongly related to diffusion-weighted indices of white matter
structural integrity in MS patients [27].
It is intuitive that MS patients would show differences in in vivo neurometabolism when
considering that postmortem analyses have revealed extensive alterations to the mitochondria in
lesioned and non-lesioned MS neural tissue [31–33], see [34–36]. For instance, Singhal and colleagues [33]
found decreases in postmortem NAA, a partial marker of neuronal respiratory capacity, and decreases
in electron transport subunit proteins across lesioned and non-lesioned MS grey matter, relative to
matched control participants’ grey matter. Taken together, the results of postmortem and in vivo
neuroimaging studies demonstrate that neurometabolic alterations are generally featured in MS.
Evaluating veCMRO2 should also be particularly relevant as a diagnostic marker of MS because
MS is marked by alterations to the neural substrate of the visual system, see [37–40] see also [5]. The use
of advanced imaging techniques such as high-resolution structural brain imaging, optical coherence
tomography (OCT), functional magnetic resonance imaging (fMRI), and diffusion tensor imaging (DTI)
has revealed that visual system alterations exist even in MS patients without visual disturbances
or a history of optic neuritis (a clinical syndrome closely linked to MS and marked by visual
impairment and visual pathway insult). Indeed, there are MS-related structural alterations to both early
(e.g., retinae) and later (e.g., optic radiations) portions of the afferent visual pathway, and alterations to
visuocortical activity in patients without a history of optic neuritis see [39]. For instance, Alshowaier
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and colleagues [41] used electroencephalogram recordings to show that MS patients without a history
of optic neuritis demonstrated delayed inion channel, multifocal visual-evoked electrical potentials
relative to age- and sex-matched HCs. Previous work in our laboratory has also revealed alterations to
visual cortex BOLD signal during visual stimulation in MS patients with normal or corrected-to-normal
vision compared to matched HCs [42], see also [43]. Together, structural and functional imaging results
suggest that changes to the visual system are a robust marker of MS pathology.
MS is associated with changes to neurometabolism and alterations to the neural substrate of
the visual system. Thus, visual-evoked oxygen metabolism signals in visual cortex (i.e., veCMRO2 )
should be a diagnostically relevant marker of MS. We assessed the extent to which veCMRO2 signals
could be used to discriminate between MS patients and HCs. The classification accuracy of veCMRO2
was examined in the context of other variables commonly assayed in MS, including measures of
neurological insult (e.g., gross lesion volume, parenchymal atrophy), neuropsychological change
(e.g., Brief Repeatable Battery of Neuropsychological Tests [44]), and self-report symptom measures
(e.g., subjective fatigue). We tested the extent to which veCMRO2 , and these other measures, could
classify MS status using both within-sample and out-of-sample observations.
2. Materials and Methods
2.1. Participants
Participants between the ages of 18 and 65 were recruited for this study. Participants were required
to be free of MR-contraindicators, concurrent substance abuse, have normal or corrected-to-normal
vision, and speak fluent English. Because study procedures included a gas-inhalation challenge
(see Section 2.4), participant selection was limited to non-smokers. Participants did not have histories
of respiratory or pulmonary problems, cerebral vascular issues, or cardiac problems. Participants were
required to have a score greater than 21 on the telephone interview for cognitive status [45]. Thirty-one
participants in total met the inclusion criteria.
Twelve MS patients meeting the above criteria were recruited from the Clinical Center for Multiple
Sclerosis at the University of Texas Southwestern Medical Center. Eleven patients had a diagnosis of
relapsing-remitting MS and one patient had a diagnosis of secondary-progressive MS. Patients were
required to be at least 1 month past their most recent exacerbation and their last corticosteroid treatment.
Patients were recruited who did not report a history of optic neuritis. Patients without a history of
optic neuritis were specifically selected so as to limit additional variability from attributed to severe,
anterior visual pathway damage/dysfunction (e.g., such as that resulting from conduction block) and
potential visual impairment. All MS patients’ vision was normal or corrected-to-normal. Two patients
withdrew or declined to undergo the gas challenge (total n = 10).
Nineteen HC participants were recruited from the Dallas-Fort Worth Metroplex via email, posted
flyers, and word-of-mouth. These participants were evaluated for the general inclusion/exclusion
criteria described above. Three HCs did not undergo the scanning protocol because of exclusions
discovered after study enrollment (e.g., concussion history revealed after pre-screening, incidental MR
finding). Two HCs withdrew or declined to undergo the gas challenge. During imaging processing
(see Section 2.5), one HC’s functional images failed to appropriately register to their anatomical image
after multiple attempts, so this person was excluded. Thirteen HCs (n = 13) remained for subsequent
analyses. These participants were closely age- and sex-matched to the MS patients (see Table 1).
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Table 1. Group Characteristics.

Age
MFIS
Sex (% female)
TICS Score
Age of MS Onset
Disease Duration
Last Flare-up
Neurological Disability Score
Disease Modifying Therapies
Dalfampridine
Dimethyl fumarate
Fingolimod
Glatiramer acetate

MS

HC

p

50.10 (3.35)
39.10 (7.62)
90.00%
27.00 (0.82)
38.67 (2.42)
118.80 (19.32)
28.60 (11.32)
15.70 (3.71)

50.77 (3.35)
20.54 (4.57)
84.62%
28.08 (1.43)
-

0.885 a
0.046 a
0.704 b
0.520 a
-

50%
10%
20%
10%

-

-

Mean (SEM). Age in years. MFIS = modified fatigue impact score total. Sex in percent female. TICS score = telephone
interview for cognitive status score. Age of MS onset in years. Disease duration and last flare-up in months.
Neurological disability score measured by self-report [46]. Disease modifying therapies represent percent of
participants reporting use of therapy. a p-value based upon independent samples t-test. b p-value based upon
Pearson χ2 .

2.2. Study Procedures
Study procedures were approved by the University of Texas Southwestern Medical Center
Institutional Review Board. Recruitment numbers were approximated based upon previous research
showing sufficient power to demonstrate group changes in calibrated fMRI (cfMRI) contrasts with
similar sample sizes [22,23]. Participants meeting inclusion criteria were asked to refrain from
caffeine use at least two hours before their scheduled appointment time, e.g., [47]. They were
also asked not to consume alcohol on the same calendar day before their scheduled appointment.
Participants gave written informed consent before undergoing procedures and were compensated
for their time. Participants underwent functional and structural neuroimaging on a Philips 3-Tesla
magnet (Philips Medical Systems, Best, The Netherlands) with an 8-channel SENSE radiofrequency
head coil. Foam padding was placed around the head to minimize motion during MRI scan
acquisition. Participants completed standard neuropsychological tests (e.g., Brief Repeatable Battery
of Neuropsychological tests [44]) and self-report measures regarding their general health and
symptomology (i.e., SF-36 [48], Modified Fatigue Impact Scale (MFIS, [49]); see Table 2 for a complete
list of model variables).
Table 2. Predictor Variables.
Predictor (Units if Available)
Normalized Grey Matter Volume (mm3 )
Normalized White Matter Volume (mm3 )
Normalized Whole Brain Volume (mm3 )
Skeleton AD (mm2 /s)
Skeleton FA (proportion)
Skeleton MD (mm2 /s)
Skeleton RD (mm2 /s)
T2 -FLAIR Lesion Burden-absolute lesion volume (mm3 )
T2 -FLAIR Lesion Burden-relative lesion volume (%)
T2 -FLAIR spatially distinct lesion count
veBOLD (% signal change)
veCBF (% signal change)
veCMRO2 (% signal change)
ven (proportion)
10/36 Delayed Recall (total correct after 15 min)
10/36 Immediate Recall (total correct)
25 Foot Walk (s)
9-Hole Peg Test-Dominant Hand (s)
9-Hole Peg Test-Non-dominant Hand (s)
Box Completion (items completed)
Controlled Oral Word Association Test (total correct)
Number Comparison (items completed)

Predictor Category

What Predictor Measures

MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
MR Image
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych

Total grey matter volume normalized to skull
Total white matter volume normalized to skull
Total brain volume normalized to skull
Diffusion along primary diffusion axis
Proportion of anisotropic diffusion
Average Diffusion in primary diffusion axes
Diffusion orthogonal to primary diffusion axis
Total volume of lesioned brain tissue
Total lesioned brain tissue relative to total white matter volume
Total number of spatially distinct lesions
Visual cortex BOLD response to visual stimulation task
Visual cortex CBF response to visual stimulation task
Visual cortex CMRO2 response to visual stimulation task
Visual cortex neural-vascular coupling
Visuospatial memory/learning and delayed recall
Visuospatial memory/learning
Walking ability and gait speed
Finger and hand dexterity
Finger and hand dexterity
Motor control
Verbal association fluency
Processing speed
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Table 2. Cont.
Predictor (Units if Available)

Predictor Category

Paced Auditory Serial Addition Test 2 (% correct)
Paced Auditory Serial Addition Test 3 (% correct)
Selective Reminding Task Delayed (items recalled)
Selective Reminding Task Long-term Storage (items recalled)
Symbol-digit Modalities Test (items completed)
Trail Making Task Form A (s)
Trail Making Task Form B (s)
Trail Making Task Form B-A (s)
WAIS-III Digit Span Backward (items completed)
WAIS-III Digit Span Forward (items completed)
WAIS-III Digit Span Total (items completed)
WAIS-III Digit symbol coding (items completed)
Modified Fatigue Impact Score
SF-36 Bodily Pain Scale
SF-36 Emotion
SF-36 General Health Scale
SF-36 Mental Health Scale
SF-36 Physical Functioning Scale
SF-36 Role Physical Function Scale
SF-36 Social Functioning Scale
SF-36 Vitality Scale

Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Neuropsych
Symptoms
Symptoms
Symptoms
Symptoms
Symptoms
Symptoms
Symptoms
Symptoms
Symptoms

What Predictor Measures
Processing speed and selective/sustained attention
Processing speed and selective/sustained attention
Verbal learning and memory
Verbal learning and long-term memory
Sustained attention and concentration
Visual search, attention, mental flexibility, and motor function
Visual search, attention, mental flexibility, and motor function
Visual search, attention, mental flexibility, and motor function
Short-term, working memory
Short-term, working memory
Short-term, working memory
Performance subtest of WAIS
Fatigue symptomology
General measure of bodily pain
Role limitations due to emotional problems
General measure of health wellbeing
General measure of mental health
General measure of physical functioning
Role limitations due to physical problems
General measure of social functioning
General measure of energy/fatigue

FLAIR = Fluid-attenuated inversion recovery. WAIS = Wechsler adult intelligent scale. SF-36 = Short-form health
survey. MR Image = magnetic resonance image; Neuropsych = neuropsychological test; Symptoms = self-report
general health and symptom measures. Explanations of neuropsychological tests and symptom measures taken
from [44,48,50,51].

2.3. cfMRI Parameters and Theory
Dual-echo pseudocontinuous arterial spin labeling (pCASL) and BOLD images (together referred
to as dual-echo images) were acquired using an interleaved echo scanning protocol see [7,52]. Together,
the perfusion (Echo 1) and BOLD-weighted (Echo 2) images along with biophysical modeling
procedures allowed for estimation of CMRO2 and a neural-vascular coupling coefficient (n, see [8])
associated with steady-state, neural stimulation [5,7]. One task run of dual-echo imaging data and one
gas-challenge run of dual-echo imaging data were collected using the following parameters: Echo 1:
labeling duration 1650 ms, labeling flip angle 18◦ , labeling gap = 63.5 mm, 3.44 × 3.44 × 5 mm voxel,
repetition time (TR) = 4000 ms, echo time (TE) = 14 ms, 1525 ms post-label delay, 0 mm slice gap.
Echo 2: 90◦ flip angle, 3.44 × 3.44 × 5 mm voxel, TR = 4000 ms, TE = 40 ms, 0 mm slice gap. Total scan
time for the visual stimulation task = 600 s (72 dual-echo dynamics). Total scan time for the gas
challenge = 624 s (75 dual-echo dynamics).
Estimations of CMRO2 and n were based upon the Davis model of BOLD signal change [6,7]:

!β 

 ∝ −β
∆CMRO2 
∆S
∆CBF
= M 1 −
(1)
S0
CBF0
CMRO2|0
where ∆x/x0 denotes a change from baseline, α is an empirically derived constant linking cerebral
blood flow and cerebral blood volume, and β is an empirically derived constant related to vascular
exchange and susceptibility of deoxyhemoglobin at specific field strengths (e.g., [53–55]). We assumed
α = 0.38 [56] and β = 1.3 [52]; these values were chosen because they have been shown to be sensitive
to group differences in neurophysiology [22,23]. Also, these values have previously demonstrated
group-equivalence in the estimation of M, e.g., [22,23]. M is a subject-specific scaling factor dependent
upon the washout resting deoxyhemoglobin see [8]. M was estimated in each participant, using the
gas challenge detailed below.
The measurement of BOLD, CBF, and M allows for the estimation of CMRO2 . Here, ∆CMRO2
reflects the visual task-related change in neurometabolism of oxygen from resting baseline:

∆BOLD 1/β



∆CMRO2
∆CBF 1− α/β
BOLD0 


= 1 −

CMRO2|0
M
CBF0


(2)
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where ∆x/x0 reflects percent change of signal during task compared to resting baseline. With the
estimation of ∆CMRO2 , n, may also be estimated:
Brain Sci. 2017, 7, 64
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(3)
(3)

thus, n reflects per unit output of ∆CBF per unit input of ∆CMRO2 see [8].
thus, n reflects per unit output of ∆CBF per unit input of ∆CMRO2 see [8].

2.4. cfMRI Task and Gas Challenge
2.4. cfMRI Task and Gas Challenge
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signal. Potential changes to oxygen metabolism due hypercapnic challenge have not been shown to
appreciably alter the estimation of M as relationships between hypercapnia-derived M and M derived
from non-hypercapnic techniques show high correspondence [64].
2.5. cfMRI Processing
Task and gas-challenge Echo 1 and Echo 2 data were processed in analysis of functional
neuroimages (AFNI [65]) and the Functional MRI of the Brain Software Library (FSL [66]). Data were
transformed into cardinal planes. Anomalous data points in each voxel time series were then attenuated
using an interpolation method based upon the average signal. Data were volume registered to correct
for motion to the fourth functional volume of each dataset’s (task or gas challenge) Echo 2 sequence
using a heptic polynomial interpolation method. CBF was estimated from Echo 1 images using the
surround subtraction method [67]. Dual-echo BOLD data were also interpolated by pairwise averaging
of temporally adjacent images.
For the visual stimulation task, Echo 2 data were linearly registered (12 degrees-of-freedom)
to each participant’s anatomical data using AFNI’s align_epi_anay.py program. The transformation
matrix from this registration was then applied to Echo 1 data, placing these two datasets in the same
space. For gas-challenge data, a binary mask was created for functional voxels in Echo 2 to aid in
co-registration. This mask was then registered to the respective participant’s anatomical space using
the align_epi_anay.py program. Gas-challenge Echo 2 and Echo 1 data were also aligned to the mask
which was registered in native anatomical space. After alignment, Echoes 1 and 2 data from both the
visual task and gas challenge were visually inspected for registration errors. One HC participant failed
to register correctly after multiple attempts and was discarded from further analyses. Echoes 1 and
2 data from the visual task and gas challenge were then spatially smoothed using a Gaussian kernel
(FWHM = 8 mm) and high-pass filtered (0.0039 Hz).
Preprocessed data from Echoes 1 and 2 in the visual stimulation task were analyzed
via generalized linear modeling of task versus rest periods using a boxcar reference function.
This modeling quantified task-related CBF and BOLD changes from baseline. BOLD and CBF
beta-values were scaled to each voxel’s resting baseline signal and were multiplied by 100, yielding
percent signal change estimates from baseline (∆BOLD and ∆CBF). Data were averaged from a visual
(functional) region of interest (ROI) comprised of overlapping ∆BOLD and ∆CBF suprathreshold
signals within occipital lobe (see Structural and Functional ROI; [22,23]). ∆BOLD, ∆CBF, ∆CMRO2 ,
and n results extracted from the functional region of interest were taken as the visual-evoked signals
(i.e., veBOLD, veCBF, veCMRO2 , and ven).
For the gas challenge, resting baseline BOLD and CBF signals during room air breathing were
averaged for each voxel time-series (BOLD0 and CBF0 ). The first two minutes of hypercapnia BOLD
and CBF time-series were discarded to allow participants’ blood flow to stabilize on the CO2 solution,
e.g., [22,23]. The last four minutes of hypercapnia BOLD and CBF time-series were averaged to yield
BOLDhc and CBFhc respectively. Average values were extracted from a functional region of interest
(see Structural and Functional ROI) using overlapping BOLDhc and CBFhc suprathreshold signals
within occipital lobe, and were used to calculate M, using the following equation:

M=

BOLDhc − BOLD0
BOLD0
CBFhc − CBF0
1− 1+
CBF0


α− β !

(4)

where (xhc −x0 )/x0 reflects percent change in signal from normocapnic to hypercapnic states,
normalized by the signals during normocapnia and multiplied by 100. Once M was estimated,
∆CMRO2 and n were also estimated (see Equations (2) and (3); see Figure 2) within a functional
region of interest (see Structural and Functional ROI).

A visual task functional ROI was created within the structural ROI described above to estimate
veBOLD, veCBF, veCMRO2, and ven (see Figure 3). This procedure eschewed noise from inactive
voxels, e.g., [68]. Voxels comprising each participant’s functional ROI were the overlapping top 5%
of BOLD and top 5% of CBF t-values obtained from the generalized model, within the structural ROI.
This ensured that average veBOLD and veCBF estimates were being derived from the same, taskvoxels and that veCMRO2 and ven were derived in voxels with both CBF and BOLD taskBrainresponsive
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Figure 2. Examples of oxygen metabolism changes (∆CMRO2)in occipital lobe. (A) HC ∆CMRO2. (B)

Figure 2. Examples of oxygen metabolism changes (∆CMRO2 )in occipital lobe. (A) HC ∆CMRO2 ;
MS patient ∆CMRO2. x = right-left, z = superior-inferior.
(B) MS patient ∆CMRO2 . x = right-left, z = superior-inferior.

veCMRO2 was calculated voxel-wise within the functional ROI using ∆BOLD, ∆CBF, M (which

2.6. was
Structural
and from
Functional
ROIsROI described below). ven was then calculated similarly. The final
extracted
functional

product
ofmagnetization-prepared
these analyses was average
positive
veBOLD,
veCBF, and (MPRAGE)
veCMRO2, and
extracted
First, the
rapid
acquisition
gradient-echo
dataven
were
processed
from the functional ROI (see Figure 3).
to create a native-space, occipital ROI. The skull was removed using an automated command,
Because the gas challenge data differed in occipital coverage compared to the visual task data,
separating parenchyma and cerebral spinal fluid from the skull. An intensity based automated
M was estimated ex situ. To create a functional ROI for the gas challenge, ∆BOLDhc/BOLD0 and

segmentation algorithm was used to delineate primarily white matter, grey matter, and cerebral
spinal fluid voxels yielding a partial volume estimate of each tissue type, for each voxel. A grey matter
mask was then created, retaining voxels with only a greater than or equal to grey matter partial volume
estimate of 80%. A structural ROI of occipital lobe was manually delineated on each participant’s
MPRAGE image. These were drawn in native space because native space analyses tend to allow for
more sensitive patient-control contrasts [68]. The structural ROI was drawn using gyral and sulcal
landmarks and encompassed most of occipital cortex including calcarine sulcus, cuneus, and occipital
portions of lingual gyrus. Several anatomical landmarks were used in the demarcation of this ROI
(parieto-occipital sulcus, occipital pole, pre-occipital notch). Within the anatomically defined occipital
lobe, only voxels with partial volume estimates of grey matter (≥80%) were retained. These final masks
were down-sampled to the functional voxel size.
A visual task functional ROI was created within the structural ROI described above to estimate
veBOLD, veCBF, veCMRO2 , and ven (see Figure 3). This procedure eschewed noise from inactive
voxels, e.g., [68]. Voxels comprising each participant’s functional ROI were the overlapping top 5%
of BOLD and top 5% of CBF t-values obtained from the generalized model, within the structural
ROI. This ensured that average veBOLD and veCBF estimates were being derived from the same,
task-responsive voxels and that veCMRO2 and ven were derived in voxels with both CBF and BOLD
task-related increases (see Figure 3).

∆CBFhc/CBF0 maps were thresholded and extracted from the structural ROI detailed above. The
criteria for retention of a voxel within these maps required that the voxel was within the top 15% (top
20% for one participant) of ∆BOLDhc/BOLD0 and ∆CBFhc/CBF0 voxels in the structural ROI, and that
these ∆BOLDhc/BOLD0 and ∆CBFhc/CBF0 voxels overlapped. This procedure ensured complementary
maximum
∆BOLDhc/BOLD0 and ∆CBFhc/CBF0 signals in the retained voxels. Average
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∆BOLDhc/BOLD0 and ∆CBFhc/CBF0 signals were extracted from this ROI and M was calculated (see
Equation (4)).

Figure
3. Graphical
overviewofofmasking
maskingprocedure.
procedure. For
5%,
overlapping
Figure
3. Graphical
overview
For each
eachparticipant,
participant,their
theirtop
top
5%,
overlapping
BOLD
and
CBF
t-statistics
(middle)
within
the
anatomical
ROI
(left,
yellow)
were
used
to
create
thethe
BOLD and CBF t-statistics (middle) within the anatomical ROI (left, yellow) were used to
create
functional ROI mask (right, yellow). Functional measures (veBOLD, veCBF, veCMRO2, and ven) were
functional ROI mask (right, yellow). Functional measures (veBOLD, veCBF, veCMRO2 , and ven) were
extracted from each participant’s functional ROI mask.
extracted from each participant’s functional ROI mask.

2.7. Structural Images

veCMRO2 was calculated voxel-wise within the functional ROI using ∆BOLD, ∆CBF,
One T1-weighted MPRAGE image was acquired for each participant: 160 slices, TE = 3.7 ms,
M (which was extracted from functional ROI described below). ven was then calculated similarly.
repetition time TR = 8.1 ms, sagittal slice orientation, 1 × 1 × 1 mm3 voxel, 12° flip angle. SIENAX
The final product of these analyses was average positive veBOLD, veCBF, and veCMRO2 , and ven
[15,69] was used to obtain measures of grey matter, white matter, and total brain volume normalized
extracted from the functional ROI (see Figure 3).
by participant’s head size. This technique uses partial volume estimation to calculate volume of
Because the gas challenge data differed in occipital coverage compared to the visual task data,
differing tissue types (see Figure 4B,C). Further, this technique takes into account lesioned tissue, as
M demarcated
was estimated
ex situ.
To (see
create
a functional
formisclassification
the gas challenge,
hc /BOLD
by lesion
masks
below),
in order toROI
avoid
of this∆BOLD
tissue. The
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/CBF
maps
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and
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above.
0 analyses were scaled estimates of each participant’s grey matter, white matter, and
these
Thetotal
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3).a voxel within these maps required that the voxel was within the top 15%
brainfor
volume
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/CBF
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washc
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A T2 fluid attenuated inversion
0 and
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that TE
these
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= 125
ms, TR
11,000 0ms,
no∆CBF
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0.45 procedure
× 0.45 × 5.00ensured
mm3
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hc=
hc /CBF
voxel, 120° refocusing
angle.
FLAIRhcimages
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lesion burden
complementary
maximum
∆BOLD
/BOLD
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ingross
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voxels.
0 and
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were
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using
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based
Average
∆BOLD
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and
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this
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and
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was
0
0
hc
hc
upon
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(i.e.,
voxels
that
were
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over
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mean
intensity).
Next,
calculated (see Equation (4)).
lesions were manually delineated from the hyperintense tissue by two trained researchers (L.H., S.F.).

2.7.Manual
Structural
Images ruled out false positives in lesion classification due to fat signals, motion,
delineation
ventricular edge effects, skull, or signal inhomogeneites [70]. Lesion burden was estimated by
One T1 -weighted MPRAGE image was acquired for each participant: 160 slices, TE = 3.7 ms,
extracting
the number of voxels that were demarcated by the automated and manual procedures.
repetition time TR = 8.1 ms, sagittal slice orientation, 1 × 1 × 1 mm3 voxel, 12◦ flip angle.
Inter-rater agreement of lesion burden was calculated using a Dice ratio (κ) of the lesion burden
SIENAX
[15,69] was used to obtain measures of grey matter, white matter, and total brain volume
estimates made by the two researchers on a sample of several subjects [71]. After the researchers were
normalized
participant’s
head
size. This
technique
partial
volume
trained onby
lesion
classification,
inter-rater
agreement
wasuses
found
to be high,
κ = estimation
0.89; where κto> calculate
0.70 is
volume
of
differing
tissue
types
(see
Figure
4B,C).
Further,
this
technique
takes
into
account
generally thought to reflect excellent inter-rater agreement [72]. Lesion burden was quantified using

lesioned tissue, as demarcated by lesion masks (see below), in order to avoid misclassification of
this tissue. The final products of these analyses were scaled estimates of each participant’s grey matter,
white matter, and total brain volume (mm3 ).
A T2 fluid attenuated inversion recovery (FLAIR) scan was also acquired for each participant:
33 slices, TE = 125 ms, TR = 11,000 ms, no slice gap, transverse slice orientation, 0.45 × 0.45 × 5.00 mm3
voxel, 120◦ refocusing angle. FLAIR images were used to estimate the extent of gross lesion burden
for each participant. Hyperintense voxels were demarcated using in-house MATLAB code based
upon slice-wise, signal intensity (i.e., voxels that were ≥1.25 SD over the slice mean intensity).
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Next, lesions were manually delineated from the hyperintense tissue by two trained researchers
(L.H., S.F.). Manual delineation ruled out false positives in lesion classification due to fat signals,
motion, ventricular edge effects, skull, or signal inhomogeneites [70]. Lesion burden was estimated
by extracting the number of voxels that were demarcated by the automated and manual procedures.
Inter-rater agreement of lesion burden was calculated using a Dice ratio (κ) of the lesion burden
estimates made by the two researchers on a sample of several subjects [71]. After the researchers were
trained on lesion classification, inter-rater agreement was found to be high, κ = 0.89; where κ > 0.70 is
Brain Sci.thought
2017, 7, 64 to reflect excellent inter-rater agreement [72]. Lesion burden was quantified
10 ofusing
22
generally
3
absolute (total mm of lesioned tissue; see Figure 4E) and relative scales (percent of total mm3 of
absolute (total mm3 of lesioned tissue; see Figure 4E) and relative scales (percent of total mm3 of
lesioned tissue scaled by uncorrected white matter volume in mm33 ). Spatially distinct lesion count
lesioned tissue scaled by uncorrected white matter volume in mm ). Spatially distinct lesion count
was also obtained by counting the number of non-touching lesions for each subject (see Figure 4F),
was also obtained by counting the number of non-touching
lesions for each subject (see Figure 4F),
e.g.,e.g.,
[73].
A lesion was required to have at least 3 mm3 volume in order to be added to the total lesion
[73]. A lesion was required to have at least 3 mm3 volume in order to be added to the total lesion
count.
Thus,
thethe
final
products
were absolute
absolutelesion
lesionvolume,
volume,
relative
lesion
volume,
count.
Thus,
final
productsofofthese
theseanalyses
analyses were
relative
lesion
volume,
andand
spatially
distinct
lesion
spatially
distinct
lesioncount.
count.

Figure 4. Diffusion and Structural Image Processing Examples. (A) Diffusion tensor imaging white

Figure 4. Diffusion and Structural Image Processing Examples. (A) Diffusion tensor imaging white
matter skeleton. (B) T1 image. (C) T1 image segmented into white matter (yellow), grey matter
matter skeleton. (B) T1 image. (C) T1 image segmented into white matter (yellow), grey matter (orange),
(orange), and cerebral spinal fluid (red) using SIENAX. (D) T2-FLAIR image. (E) Lesions demarcated
and cerebral spinal fluid (red) using SIENAX. (D) T2 -FLAIR image. (E) Lesions demarcated (yellow)
(yellow) on T2-FLAIR image used for calculating lesion burden. (F) Spatially distinct lesions
on T2 -FLAIR image used for calculating lesion burden. (F) Spatially distinct lesions demarcated on
demarcated on T2-FLAIR image.
T2 -FLAIR image.

2.8. Diffusion Images

2.8. Diffusion Images

DTI images were acquired using a single-shot, echo-planar imaging sequence with a Sensitivity
DTI images
were
acquired
using
a single-shot,
imaging
sequence
with=a224
Sensitivity
Encoding
parallel
imaging
scheme
(reduction
factorecho-planar
= 2.3), 112 × 112
matrix,
field of view
× 224
mm2 (nominal
resolution
of 2 mm),
65 slices
(0 mm
gap),
thickness
2 mm,
TR = =
7.78
= 97
Encoding
parallel imaging
scheme
(reduction
factor
= 2.3),
112slice
× 112
matrix,=field
of view
224s,×TE
224
mm2
ms.
The
diffusion
weighting
was
encoded
along
30
independent
orientations
[74]
and
the
b
value
was
(nominal resolution of 2 mm), 65 slices (0 mm gap), slice thickness = 2 mm, TR = 7.78 s, TE = 97 ms.
Imaging time
was
5 min and
15 s.30Two
HCs did not
undergo DTI
(nHC
s/mm2.weighting
The1000
diffusion
was
encoded
along
independent
orientations
[74]
and= 11).
the b value was
2
Automatic
Image
Registration
[75]
was
performed
on
raw
diffusion-weighted
images
to correct
1000 s/mm . Imaging time was 5 min and 15 s. Two HCs did not undergo DTI (nHC = 11).
distortion
caused
by
eddy
currents.
Six
elements
of
the
3
×
3
diffusion
tensor
were
determined
by
Automatic Image Registration [75] was performed on raw diffusion-weighted images to correct
multivariate least-squares fitting. The tensor was diagonalized to obtain three eigenvalues (λ1–3) and
distortion caused by eddy currents. Six elements of the 3 × 3 diffusion tensor were determined by
eigenvectors (v1–3). Standard tensor fitting was conducted with DTIStudio [76] to generate the most
multivariate least-squares fitting. The tensor was diagonalized to obtain three eigenvalues (λ1–3 )
common DTI-derived diffusion characteristics, fractional anisotropy (FA), axial diffusivity (AD),
mean diffusivity (MD), and radial diffusivity (RD).
DTI measurements were obtained at the skeletons of the white matter using FSL [77] to alleviate
partial volume effects with tract-based spatial statistics (see Figure 4F–H) [77]. Participant FA maps
were registered nonlinearly to the EVE single-subject FA template [78–80] for better alignment with
a digital white matter atlas (JHU ICBM-DTI-81) [81]. Registered FA maps of all subjects were
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and eigenvectors (v1–3 ). Standard tensor fitting was conducted with DTIStudio [76] to generate the
most common DTI-derived diffusion characteristics, fractional anisotropy (FA), axial diffusivity (AD),
mean diffusivity (MD), and radial diffusivity (RD).
DTI measurements were obtained at the skeletons of the white matter using FSL [77] to alleviate
partial volume effects with tract-based spatial statistics (see Figure 4F–H) [77]. Participant FA maps
were registered nonlinearly to the EVE single-subject FA template [78–80] for better alignment with
a digital white matter atlas (JHU ICBM-DTI-81) [81]. Registered FA maps of all subjects were averaged
to generate a mean FA map, from which an FA skeleton mask was created. Skeletonized FA images of
all subjects were obtained by projecting the registered FA images onto the mean FA skeleton mask.
Skeletonized AD, MD, and RD metrics were obtained by applying the same registration, projection,
and skeletonization procedures. We extracted skeleton-wide averages of each DTI metric (i.e., AD, FA,
MD, RD), wherein an average of each metric is calculated across all voxels within the white matter
skeleton (see Figure 4A).
2.9. Statistical Analyses
All analyses were performed on distributions free of outliers (≥±2 SD from group mean for simple
group comparisons, ≥±3 MAD from group median for classification modeling see [82]). Binary logistic
regression was used for classifying MS status. A description of model variables can be found in Table 2.
The accuracies of these models were computed as the proportion of correct classification outcomes
over all outcomes. Accuracy was chosen as the metric of interest because it combines sensitivity
and specificity in binary classification analysis by taking into account both true positives and true
negatives relative to all outcomes. We used resampling-based hypothesis testing to examine both
within-sample and out-of-sample classification of patient status see [83]. Because we used relatively
conservative analytic techniques, inherently reducing the likelihood of Type I error and increasing the
generalizability of our results, the criterion for a rejection of the null hypothesis was not corrected for
multiple comparisons and all models were evaluated at the field-standard α = 0.05. We also denote
which hypothesis tests survived Benjamini-Hotchberg correction (Table 4; Figure 7).
Within-sample classification analyses obtained bias-corrected and accelerated (BCa) bootstrappedresampled (B = 10,000) 95% confidence intervals of the accuracy of binary logistic regression models.
The BCa procedure was used because it is robust to both skewness and sampling bias in the bootstrap
distribution [84]. To avoid unstable classification, we stratified all resamples to match the original
sample’s constitution of patients and controls, 56.5% and 43.5%, respectively. If the BCa-derived 95%
confidence interval did not contain a value at or below 0.50 (binary chance), this would demonstrate
the measure’s accuracy was significantly greater than chance to classify MS patients and HCs.
Out-of-sample classification analyses used a leave-one-out cross-validation approach [85].
This technique used training and sample iterations to test the ability of the model derived from
the training set to predict an observation in the test (out-of-sample) set, thus, circumventing
problems of sample bias, model over fitting, and lending a true predictive element to these analyses.
Briefly, the leave-one-out cross validation (LOOCV) approach fitted N models, where N was
proportional to our sample size. Each model was trained on N-1 samples and then the accuracy
of the training model was assessed on the left-out sample. The N accuracies were then averaged to
attain a representative and generalizable measure of the average out-of-sample classification accuracy.
Permutation based p-values (5000 permutations) were computed to assess the significance of the
LOOCV-derived accuracy statistics. The test permuted patient status labels and recomputed the
accuracy of the model at each iteration, thus building the null distribution. The p-values were calculated
from the percentage of the accuracy estimates of the permuted samples that were better than actual
LOOCV-derived accuracy statistic of each model. This procedure was slightly modified according to
Ojala and Garriga [86].
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3. Results
3.1. Visual Task Performance
MS patients (92.75 ± 1.11%) did not significantly differ from HCs (94.86 ± 0.44%) on accuracy on
the visual stimulation secondary task, t(10.54) = −1.76, p = 0.108. Patients (492.06 ms ± 31.15) also did
not significantly differ from HCs (487.19 ms ± 24.10) on their average correct response time to press
the button on the secondary task, t(16.22) = 0.12, p = 0.903.
3.2. Group Physiology, Cerebrovascular Response to Gas Challenge, and M
MS and HCs did not significantly differ in breath rate, end-tidal CO2 , heart rate, or O2 saturation
at baseline or during CO2 solution breathing (all ps > 0.05; see Table 3). We tested whether MS patients
differed in their CBF response to the CO2 solution ((CBFhc −CBF0 )/CBF0 ) and M in their respective
gas challenge ROIs within occipital lobe see [87]. MS patients did not significantly differ in CBF
response to the CO2 solution (167.48 ± 19.8%) compared to HCs (146.90 ± 14.64%), t(15.70) = 0.83,
p = 0.417. MS patients (3.88 ± 0.48%) did not significantly differ in M compared to HCs (5.11 ± 0.39%),
t(18.90) = −1.98, p = 0.062.
Table 3. Sample Physiological Data.
MS

HC

p

Baseline
Breath Rate
EtCO2
Heart Rate
SpO2

11.20 (1.00)
42.70 (1.81)
66.90 (2.38)
98.10% (0.35%)

10.25 (0.79)
39.23 (0.74)
72.08 (3.18)
97.85% (0.32%)

0.747 a
0.101 b
0.207 b
0.596 b

5% CO2
Breath Rate
EtCO2
Heart Rate
SpO2

13.35 (1.28)
48.95 (1.45)
69.67 (2.38)
97.58% (0.39%)

15.42 (1.07)
49.06 (0.64)
75.04 (2.60)
98.20% (0.20%)

0.236 c
0.950 c
0.147 d
0.139 d

Mean (SEM). Breath Rate in breaths per minute. EtCO2 = end-tidal CO2 in mmHg. Heart Rate in beats per minute.
SpO2 = peripheral oxygen saturation in percent hemoglobin saturation. p-values were based on independent
samples. a 22 degrees-of-freedom; b 21 degrees-of-freedom; c 16 degrees-of-freedom; d 17 degrees-of-freedom.

3.3. Group Comparisons on Visual Task cfMRI Measures
MS patients (1.12 ± 0.77%) did not significantly differ from HCs (1.18 ± 0.66%) on veBOLD
response to visual stimulation, t(19.18) = −0.60, p = 0.555. MS patients (4.08 ± 0.35) did not
show significant changes in ven compared to HCs (4.23 ± 0.23), t(16.16) = −0.35, p = 0.731.
MS patients (48.06 ± 12.58%) had significant decreases in veCBF compared to HCs (92.68 ± 17.29%),
t(19.76) = −2.09, p = 0.050. MS patients (9.59 ± 0.90%) also showed significant decreases in veCMRO2
compared to HCs (17.85 ± 1.97%), t(16.45) = −3.81, p = 0.002 (see Figure 5).
3.4. Within-Sample Classification Analyses
Measures are ranked on original accuracy and presented in Table 4. Accuracy and smoothed
density distributions for the significant and bottom 5 measures can be found in Figure 6.
3.5. Out-of-Sample Classification Analyses
Predictors presented in Figure 7 are ranked on LOOCV-derived accuracy.

MS patients (1.12 ± 0.77%) did not significantly differ from HCs (1.18 ± 0.66%) on veBOLD
response to visual stimulation, t(19.18) = −0.60, p = 0.555. MS patients (4.08 ± 0.35) did not show
significant changes in ven compared to HCs (4.23 ± 0.23), t(16.16) = −0.35, p = 0.731. MS patients (48.06
± 12.58%) had significant decreases in veCBF compared to HCs (92.68 ± 17.29%), t(19.76) = −2.09, p =
0.050.
MS7,patients
(9.59 ± 0.90%) also showed significant decreases in veCMRO2 compared to HCs
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(17.85 ± 1.97%), t(16.45) = −3.81, p = 0.002 (see Figure 5).
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Figure 6. Smoothed density estimates of BCa-bootstap distributions. Distributions of significant
Figure 6. Smoothed density estimates of BCa-bootstap distributions. Distributions of significant (solid
(solid lines) and bottom 5 (dashed lines) within-sample predictors of MS status are illustrated.
lines) and bottom 5 (dashed lines) within-sample predictors of MS status are illustrated. Note: because
Note:
of smoothing,
tails of distributions
of because
smoothing,
tails of distributions
may exceed 1.may exceed 1.
Table 4. Accuracy and 95% Confidence Limits of Within-Sample Classification Analyses.
Predictor

Predictor Accuracy

95% LCL

95% UCL

Significant

SF-36 Physical Functioning Scale

0.94

0.65

1.00

Yes †

SF-36 Social Functioning Scale

0.89

0.61

0.94

Yes †

T2-FLAIR spatially distinct lesion count

0.86

0.57

0.95

Yes †

Box Completion

0.86

0.52

0.95

Yes †

SF-36 Role Physical Function Scale

0.85

0.60

0.95

Yes †

veCMRO2

0.82

0.55

0.91

Yes ‡

Normalized Grey Matter Volume

0.81

0.43

0.95

No ‡

T2-FLAIR Lesion Burden-absolute lesion volume

0.80

0.50

0.90

No ‡

Brain Sci. 2017, 7, 64

14 of 23

Table 4. Accuracy and 95% Confidence Limits of Within-Sample Classification Analyses.
Predictor

Predictor Accuracy

95% LCL

95% UCL

Significant

SF-36 Physical Functioning Scale
SF-36 Social Functioning Scale
T2 -FLAIR spatially distinct lesion count
Box Completion
SF-36 Role Physical Function Scale
veCMRO2
Normalized Grey Matter Volume
T2 -FLAIR Lesion Burden-absolute lesion volume
T2 -FLAIR Lesion Burden-relative lesion volume
SF-36 Emotion
9-Hole Peg Test-Non-dominant Hand
SF-36 General Health Scale
veCBF
Normalized Whole Brain Volume
9-Hole Peg Test-Dominant Hand
SF-36 Bodily Pain Scale
Skeleton AD
Skeleton MD
Paced Auditory Serial Addition Test 2 s
Modified Fatigue Impact Score Total
Normalized White Matter Volume
Paced Auditory Serial Addition Test 3 s
Skeleton RD
Trail Making Task Form A
SF-36 Vitality Scale
25 Foot Walk
WAIS-III Digit Span Backward
WAIS-III Digit Span Total
10/36 Delayed Recall
Trail Making Task Form B
SF-36 Mental Health Scale
veBOLD
Selective Reminding Task Delayed
Symbol-digit Modalities Test
Number Comparison
WAIS-III Digit symbol coding
Skeleton FA
ven
Selective Reminding Task Long-term Storage
Controlled Oral Word Association Test
10/36 Immediate Recall
WAIS-III Digit Span Forward
Trail Making Task Form B-A

0.94
0.89
0.86
0.86
0.85
0.82
0.81
0.80
0.80
0.78
0.77
0.77
0.75
0.73
0.73
0.73
0.71
0.71
0.71
0.70
0.68
0.68
0.67
0.65
0.65
0.64
0.64
0.64
0.63
0.62
0.62
0.61
0.60
0.60
0.59
0.58
0.57
0.57
0.57
0.57
0.52
0.50
0.48

0.65
0.61
0.57
0.52
0.60
0.55
0.43
0.50
0.50
0.56
0.55
0.50
0.45
0.45
0.50
0.45
0.43
0.48
0.48
0.43
0.45
0.45
0.48
0.43
0.43
0.50
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LCL = lower confidence limit. UCL = upper confidence limit. Confidence limits based upon 10,000 iteration
BCa-corrected bootstrapping procedure.Yes = 95% confidence interval (CI) does not contain 0.50; No = 95% CI
contains 0.50. Note: that the original parameter estimates do not necessarily need to lie within the 95% CI of the
BCa-corrected, empirically derived distributions. † permutation p-value significant using Benjamini-Hotchberg
correction (p < 0.05). ‡ permutation p-value marginally significant using Benjamini-Hotchberg correction (p < 0.10).

Brain Sci. Brain
2017, 7, Sci.
64

2017, 7, 64

15 of 22

15 of 23

Figure 7. Leave-one-out
(LOOCV)
out-of-sample classification
accuracy of
each model. * p < 0.05;
** = p < 0.01; *** =accuracy
p < 0.001. † p-value
also significant
Figure 7. cross-validation
Leave-one-out
cross-validation
(LOOCV)
out-of-sample
classification
of each
using Benjamini-Hotchberg correction (p < 0.05). ‡ p-value marginally significant using Benjamini-Hotchberg correction (p < 0.10).

model. * p < 0.05; ** = p < 0.01; *** = p < 0.001. † p-value also significant using Benjamini-Hotchberg
correction (p < 0.05). ‡ p-value marginally significant using Benjamini-Hotchberg correction (p < 0.10).
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4. Discussion
In the present study, we used a neuroimaging approach novel to MS research (cfMRI) to assess the
accuracy of veCMRO2 in classifying MS patients and closely age- and sex-matched HC participants.
MS patients showed similar responses to HCs in veBOLD and ven, however showed decreased
veCBF and a pronounced decrease in veCMRO2 relative to HCs. Groups were similar on visual
task performance and on physiological measures pertaining to the CO2 challenge, indicating that
potential MS-related changes in physiological response to carbon dioxide, e.g., [87] or visual attention
were not likely contributors to group CMRO2 differences. Within-sample classification analyses
demonstrated that veCMRO2 was significant and one of the top measures to accurately classify
MS status, discriminating between MS patients and HCs with exceptional accuracy (82%). Results also
showed that within-sample classification accuracy by veCMRO2 was comparable to neuroimaging
measures often used to gauge MS pathology, such as T2 -FLAIR lesion burden (80% accuracy) and T1
grey matter volume (81% accuracy). veCMRO2 was also significantly accurate in MS classification
using out-of-sample observations (77% accuracy). The use of such out-of-sample modeling afforded
a predictive element to this study and demonstrated that veCMRO2 can accurately classify new
observations of MS and HC participants, offering support for its potential diagnostic utility.
One question that arises from these results is whether veCMRO2 can add predictive value over
other advanced imaging techniques not studied here. For instance, measurements of multifocal
visual-evoked potentials have been of great interest to the MS research community. This technique,
which uses visual stimulation and electroencephalogram signals in occipital channels proximal to the
inion has been demonstrated to (1) more sensitively and specifically detect visual abnormalities in
MS eyes relative to other visual-system measurements [88], (2) predict conversion to an MS diagnosis
in persons with optic neuritis [89], and (3) relate to the extent of MS-related damage to visual white
matter tracts [41]. Not surprisingly, this technique can also accurately discriminate between MS patients
and HCs, e.g., [90]. For example, one study showed that measurements gathered from multifocal
visual-evoked potentials were on average 74.76% accurate (range: 62.7%–96.1%) in classifying
within-sample observations of MS patients without optic neuritis and HCs ([90], average calculated
from Figures 5 and 6, pp. 910–911). We can compare these figures with the within-sample accuracy
of veCMRO2 observed here (82%). This suggests that veCMRO2 accuracy is in about the same range
as multifocal evoked potentials. However, it performs appreciably better than the average multifocal
evoked potential measure. Future research directly comparing veCMRO2 to electroencephalogram
and other measures is necessary to more faithfully adjudicate claims about the relative performance of
this technique.
A second avenue for future research could involve examining whether the integration of evoked
CMRO2 from other neural systems could maximize MS classification accuracy. Here, we showed
significant decreases in MS patients’ veCMRO2 relative to HCs. This variable was also largely accurate
in the prediction of MS status. We looked at veCMRO2 specifically because of robust alterations to
the visual system in MS see [37–40]. However, because (1) mitochondrial alterations are found in
multiple forms of neural tissue in MS [31,33] and (2) global brain decreases in oxygen metabolism
have been found in MS patients relative to HCs [30], it is likely that evoked CMRO2 is affected in
other neural systems as well. Our work and others’ have shown altered patterns of brain activity in
MS patients in motor, e.g., [42,91,92] and association cortices [43,93–95], see [96]. It is possible that the
addition of measures of evoked CMRO2 in these areas could lend improvements in the accuracy of MS
classification. One advantage of the cfMRI approach over other advanced imaging approaches in MS,
like OCT or visual-evoked potentials, is that this technique can specifically and simultaneously assay
multiple neural systems. Work underway in our laboratories is examining the extent to which evoked
motor and executive system CMRO2 differs between MS patients and age- and sex-matched healthy
HCs, and whether these changes, along with veCMRO2 , can help build optimal neurodiagnostic
models of MS.
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The utility of imaging biomarkers in MS is not limited to assisting in diagnosis see [97].
For instance, OCT measures have been shown to be effective in predicting brain atrophy and visual
acuity loss in MS see [38]. The retinal nerve fiber thickness and macular volume measures from
OCT might also be useful in differentiating different subtypes of MS [98]. Other imaging-based
measures, such as T2 -lesion burden, have shown prognostic ability by prediction of future MS disability,
e.g., [99], see also [100–102]. One potential avenue for future research is to evaluate the use of oxygen
metabolism signals in MS prognosis. For example, Ge and colleagues’ [27] research showed that lower
resting brain-wide levels of oxygen metabolism were associated with both increased neurological
disability and increased lesion burden in MS patients. Although these findings were cross-sectional,
they suggested that oxygen metabolism could be a marker of the trajectory of disease course. To wit,
future longitudinal work should examine whether measures of oxygen metabolism in early MS can
predict future disease progression cf. [89]. veCMRO2 or resting oxygen metabolic markers could also be
evaluated for their abilities to predict the transition from risk states (such as clinically or radiologically
isolated syndrome) to clinically definite MS see [100,102,103].
A recent wave of findings related to metabolic dysfunction in MS has led to metabolic hypotheses
to explain the pathophysiology of MS see [34–36]. For instance, Paling and colleagues furthered
an energy failure hypothesis of the pathophysiology of MS [35,104]. These authors postulated a link
between white matter damage and energy demand in MS, wherein this damage causes neuroenergetic
demand to exceed the supply of metabolic substrate. This hypothesis is largely consistent with the
findings of the present study, wherein the observed relative decrease in veCBF (the supply of oxygen
and glucose) in MS might have limited the neurometabolic response (veCMRO2 ) relative to HCs.
Further, issues of oxygen extraction due to mitochondrial damage/dysfunction could have also
contributed to the relative decrease in veCMRO2 for MS patients relative to HCs see [34–36].
Imaging techniques here and elsewhere have produced convincing biomarkers of MS
see [38,97,100]. However, MS is a complex, multifaceted disease. Thus, it is not surprising that our
results revealed a diverse array of measures that were accurate in classifying MS patients and HCs.
The goal of this work was to examine the ability of a new marker (veCMRO2 ) to accurately classify MS.
However, a truly prodigious advance in MS diagnostics will likely evolve from models that combine
many relevant factors. It is possible that a “gold-standard” model of MS diagnostics would contain
information about evoked CMRO2 , along with other information like lesion count, self-reported
symptomology, neuropsychological performance, and potentially other strong associates of MS not
examined here (e.g., low-contrast letter acuity performance see [105], oligoclonal band status [106],
retinal nerve fiber layer thickness see [38]). For instance, research from the Alzheimer’s Disease
Neuroimaging Initiative showed that a complement of multimodal neuroimaging, cerebrospinal fluid
proteins, along with standard clinical evaluations allow for optimal prediction of conversion from mild
cognitive impairment to Alzheimer’s disease [107]; see also [108] for application in psychiatry.
5. Conclusions
This study was the first to apply cfMRI in an MS sample. Presently, the intricacies of cfMRI
acquisition and post-acquisition processing probably hinder it from having an immediate impact
upon routine diagnosis or tracking of MS. However, acquisition continues to be optimized and
research is showing promise toward eliminating the gas-challenge component of this method, see [8],
which should increase the ease of cfMRI administration and the diversity of patients in which it
can be applied. With contemporary research highlighting the importance of neurometabolism in
the pathophysiology of MS and continued optimization of this technique, cfMRI shows promise as
a translational diagnostic/prognostic tool for MS.
Our findings demonstrated that veCMRO2 was accurate in classifying both within- and
out-of-sample observations of MS patients and HCs. Out-of-sample analyses suggested that predictive
models using veCMRO2 could be useful in MS diagnostics and potentially new cases of MS. Although
out-of-sample analyses provide confidence in the generalizability of our findings, larger, independent
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samples are desirable to confirm the robustness of these effects. However, the present findings represent
an encouraging first step in realizing the diagnostic relevance of veCMRO2 in MS.
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